Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.
Fefer
A
A
Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle 98195.
Benyunes
M C
MC
Massumoto
C
C
Higuchi
C
C
York
A
A
Buckner
C D
CD
Thompson
J A
JA
D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006402:Hematologic Diseases / Q000628:therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated; D007938:Leukemia / Q000628:therapy*; D008223:Lymphoma / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007376:Interleukin-2; D011994:Recombinant Proteins